TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7486485
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (eicosapentaenoic and docosahexaenoic acids), 4 g/d
Study: 7486485
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil placebo, 4 g/d
Study: 453056
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of about 280 mg N/kg per day (mixed animal and plant protein sources) for 8 weeks
Study: 453056
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of about 90 mg N/kg per day (egg protein) for 11 weeks
Study: 31605197
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g inulin plus 10 g resistant maltodextrin
Study: 31605197
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g placebo supplementation
Study: 31290566
Drug: Regorafenib pharmacokinetics
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib pharmacokinetics in major gastrectomy
Study: 31290566
Drug: Regorafenib pharmacokinetics
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib pharmacokinetics in no/nonsignificant gastrectomy
Study: 27508295
Drug: Serum IGF-1
Normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Serum IGF-1 levels in SGA infants (27.6 ± 17.7 ng/ml)
Study: 25172025
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (tDCS and sertraline)
Study: 24136883
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without bevacizumab
Study: 18951992
Drug: Liposomal amphotericin-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal amphotericin-B (L‐AmB)
Study: 2262461
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 250 mg oral doses
Study: 434096
Drug: Sucrose gradient
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose gradient purified vaccine
Study: 434096
Drug: Genetron purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetron purified vaccine
Study: 26081597
Drug: 5-hydroxytryptamine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment
Study: 23404064
Drug: Bromocriptine (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (dopamine receptor agonist)
Study: 21367927
Drug: TPD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPD 20 μg daily
Study: 20396750
Drug: Afobazole (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afobazole (30-60 mg/day for 1 month)
Study: 11331253
Drug: phVEGF‐2 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: phVEGF‐2 (200 microgram total dose, 6 injections of 6.0 mL)
Study: 7993958
Drug: d-amphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.5 mg/kg orally)
Study: 3053312
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid regimen (1 tablet q.i.d.; acid-neutralizing capacity, 120 mmol/day)
Study: 30373502
Drug: Mobility Feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobility Feedback Device (MFD) used weekly for 6 months
Study: 29267990
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral electroconvulsive therapy
Study: 29267990
Drug: Algorithm-based pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based pharmacologic treatment
Study: 26432772
Drug: Chlorella supplement
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplement (4 tablets, total chlorophyll ≈8.3 mg/tablet, three times a day for 2 weeks)
Study: 26432772
Drug: Chlorella supplement
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplement
Study: 19034737
Drug: Naltrexone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone at 150 mg/day
Study: 11207640
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) at 3 IU/(m(2) body surface.day)
Study: 11207640
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) at 6 IU/(m(2) body surface.day)
Study: 11207640
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH)
Study: 7989081
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily, adjusted to 10 mg once daily if necessary after 2 weeks
Study: 2460421
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education programs presented at three critical points: Pretreatment, Treatment Week 2, and Final Treatment Week.
Study: 2460421
Drug: Final Treatment
Normalized name: SUSPENSION, ORAL (FINAL DOSE FORM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final Treatment Week program with pretest.
Study: 27380862
Drug: topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 20% vitamin C
Study: 19023827
Drug: Conventional cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarettes (6-mg or 11-mg FTC tar product)
Study: 9552785
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline 10 mL at 5 minutes after spinal injection (group A)
Study: 9552785
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline 10 mL at 20 minutes after spinal injection (group B)
Study: 9552785
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline 10 mL at 7 minutes after spinal injection (group D)
Study: 9552785
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 10 mL at 7 minutes after spinal injection (group E)
Study: 9552785
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural injection (group F)
Study: 3395540
Drug: Water 100
Normalized name: water 1000 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 100 ml administered 2 hours before operation
Study: 30896629
Drug: Povidone-iodine suppository
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine suppository
Study: 30896629
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no povidone-iodine suppository)
Study: 28177167
Drug: Ketamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.1 mg/kg)
Study: 25488965
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at high-accruing centers (HHACs)
Study: 25488965
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at historically low-accruing centers (HLACs)
Study: 25488965
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at HLACs with radiotherapy compliance adjustment
Study: 19583932
Drug: Chinese compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese compound herbal medicine for reinforcing qi, activating blood circulation, expelling phlegm and dredging collaterals + simvastatin
Study: 17081270
Drug: Efalizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (1.0 mg/kg/week for 12 weeks)
Study: 17081270
Drug: Efalizumab re-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab re-treatment after relapse
Study: 17081270
Drug: Efalizumab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (initial treatment)
Study: 31527020
Drug: MTBDRplus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTBDRplus group (discontinuation of ethambutol based on MTBDRplus assay results)
Study: 31527020
Drug: Guideline group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline group (discontinuation of ethambutol based on phenotypic drug susceptibility test)
Study: 18383967
Drug: Sevo-N2O group
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevo-N2O group inhaled 8% sevoflurane in a 60/40% mixture of oxygen and N2O
Study: 1600930
Drug: Calcium (3
Normalized name: bicarb dialy soln 7-no pot,dex calcium (3.5 mEq/L)-magnesium (1 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (3 mg) added to meals containing iron (0.01 mg)
Study: 31478126
Drug: Passive myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive myofunctional therapy (PMFT) using an oral device nightly for 1 year
Study: 31478126
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral device)
Study: 29929533
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and dexmedetomidine
Study: 29929533
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and propofol
Study: 26178202
Drug: Computer-generated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-generated treatment preferences
Study: 20717126
Drug: L-ornithine hydrochloride
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine hydrochloride (0.1 g/kg body mass)
Study: 12485262
Drug: Adjuvant antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant antithrombotic therapy (platelet aggregation inhibitors and heparins)
Study: 9660243
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenge
Study: 26030651
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg/day for 12 months
Study: 10984252
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at a dose of 0.6 IU/kg/day (0.2 mg/kg/day)
Study: 10984252
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I) stimulated through the GH axis
Study: 8960082
Drug: Dobutamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine with low dose dipyridamole
Study: 3009633
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine (MMU 18006)
Study: 10423637
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) therapy
Study: 3303944
Drug: Single-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose piperacillin (4 gm intravenously)
Study: 3303944
Drug: Multiple-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose piperacillin (three 2 gm doses intravenously 4 hours apart)
Study: 24943065
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery for 4 weeks overnight
Study: 24943065
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy for 4 weeks overnight (control)
Study: 18692805
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg daily (n = 26)
Study: 18692805
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg daily (n = 26)
Study: 10687834
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy (valerate estradiol‐‐2 mg/day for 21 days and cyproterone acetate‐‐1 mg/day for 10 days)
Study: 22883122
Drug: Human aspart
Normalized name: insulin aspart, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human aspart insulin
Study: 21396140
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of fructose/d for 4 weeks
Study: 21396140
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of glucose/d for 4 weeks
Study: 12127050
Drug: Anthrax vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthrax vaccine (specific lots containing squalene)
Study: 12127050
Drug: Anthrax vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthrax vaccine (general AVIP participants)
Study: 9843287
Drug: Visual cue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual cue triggering with 75 ml of contrast agent at 1.5 ml/sec
Study: 9843287
Drug: Automated ROI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated ROI threshold triggering with 75 ml of contrast agent at 1.5 ml/sec
Study: 9843287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 150 ml of contrast agent at 1 ml/sec
Study: 8078551
Drug: Cytarabine 100
Normalized name: cytarabine 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine 100 mg/m²/day for 5 days by continuous infusion
Study: 8078551
Drug: Cytarabine 400
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 400 mg/m²/day for 5 days by continuous infusion
Study: 8078551
Drug: Cytarabine 3
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 3 g/m² in a 3-hour infusion every 12 hours on days 1, 3, and 5
Study: 30787295
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of modified mRNA encoding VEGF‐A
Study: 28106245
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg/day) + active lifestyle intervention
Study: 28106245
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg/day) alone
Study: 24122176
Drug: Acetaminophen (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1.5 g)
Study: 17427914
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for chronic nightmares
Study: 16268466
Drug: Ximelagatran (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (24 mg twice daily)
Study: 7564328
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ro 40‐5967 in 60 min
Study: 7564328
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ro 40‐5967 in 30 min
Study: 7564328
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Ro 40‐5967 in 15 min
Study: 7564328
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Ro 40‐5967 in 30 min (two simultaneous doses of 40 mg)
Study: 7564328
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Ro 40‐5967 in 30 min (one arm)
Study: 1682645
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa octavalent O‐polysaccharide‐toxin A conjugate vaccine
Study: 6185060
Drug: Loperamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide at a dose of 0.2 mg/kg/day
Study: 30592390
Drug: Single-dose umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline (20 × 10^6)
Study: 25256258
Drug: Abediterol 25
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 25 μg
Study: 17241864
Drug: Reducing peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing peginterferon alfa-2a dose to < or =60%
Study: 17241864
Drug: Full-dose peginterferon
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose peginterferon alfa-2a (> or =98%) with ribavirin dose reduced to < or =60%
Study: 17241864
Drug: Full-dose peginterferon
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose peginterferon alfa-2a with prematurely discontinued ribavirin
Study: 7697848
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg rPF4
Study: 7697848
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg rPF4
Study: 7697848
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg rPF4
Study: 7697848
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg rPF4
Study: 7697848
Drug: rPF4 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rPF4 administration
Study: 29559423
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg)
Study: 29559423
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 mg)
Study: 28301264
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with a median prescription dose of 70 Gy
Study: 28301264
Drug: Mean heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean heart dose
Study: 25935340
Drug: Preoperative hyperosmotic
Normalized name: HYPEROSMOTIC LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hyperosmotic treatment with sodium chloride 5% ophthalmic ointment (Muro‐128)
Study: 25935340
Drug: Control eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eyes (no hyperosmotic treatment)
Study: 23806384
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate (250 ml beetroot juice)
Study: 23806384
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate capsules (KNO3, 8 mmol)
Study: 21457238
Drug: telcagepant +
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant + ibuprofen 280 mg + ibuprofen 400 mg
Study: 21457238
Drug: telcagepant +
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant + acetaminophen 280 mg + acetaminophen 1000 mg
Study: 17702703
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus an additional session of standing practice
Study: 15383482
Drug: IV tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tissue plasminogen activator (tPA) if treatment is initiated within 3 h of symptom onset
Study: 15383482
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for patients with extensive and clearly identifiable hypodensity on CT
Study: 15383482
Drug: Full-dose anticoagulation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anticoagulation with IV or subcutaneous heparins or heparinoids
Study: 15383482
Drug: Early aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early aspirin therapy, 160 to 325 mg qd
Study: 15383482
Drug: Prophylactic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic low-dose subcutaneous heparin or low molecular weight heparins or heparinoids for AIS patients with restricted mobility
Study: 15383482
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression devices or elastic stockings for patients with contraindications to anticoagulants
Study: 15383482
Drug: Antiplatelet agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agent treatment (including aspirin, combination of aspirin and extended-release dipyridamole, or clopidogrel) for noncardioembolic stroke or TIA
Study: 15383482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and extended-release dipyridamole over aspirin
Study: 15383482
Drug: Clopidogrel over
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel over aspirin for noncardioembolic stroke or TIA
Study: 15383482
Drug: Clopidogrel for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel for patients allergic to aspirin
Study: 15383482
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulation for patients with atrial fibrillation and a recent stroke or TIA
Study: 15383482
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin or low molecular weight heparin for patients with venous sinus thrombosis during the acute phase